Octanate (Human Coagulation Factor Viii)

Human Coagulation Factor VIII, the active ingredient in Octanate, is a coagulation factor replacement therapy presented as an intravenous solution for intravenous use. It treats hemophilia A by providing the missing clotting protein in patients with this inherited bleeding disorder.

GNH USA supplies Octanate as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Octanate is used in the management of bleeding disorders that involve the intrinsic coagulation pathway, particularly hemophilia A. - Hemophilia A (moderate to severe): provides factor VIII replacement to control and prevent bleeding episodes. - Hemophilia A during surgery or invasive procedures: ensures adequate hemostasis before, during, and after the procedure. - Acquired factor VIII deficiency: supplies the missing factor VIII to restore normal clotting function.

Adverse reactions to Octanate are generally related to infusion and immune responses.

Common Side Effects: - Headache - Fever - Nausea - Mild rash or itching - Transient elevation of liver enzymes - Mild infusion site discomfort

Serious or Rare Side Effects: - Development of inhibitory antibodies against factor VIII - Severe allergic reactions including anaphylaxis - Thromboembolic events - Severe hemolysis - Acute renal failure - Disseminated intravascular coagulation (DDI)

When using Octanate, several important safety considerations should be observed: - Monitor  ":   -  ".  """"  " ".   ""  """ \